The company's lead assets include NC410, a fusion protein of LAIR-2 that demonstrated early clinical activity in colorectal and ovarian cancers in combination with pembrolizumab, and LNCB74, an ADC directed to B7-H4. NextCure is also seeking partners for clinical programs NC525 and NC318, and preclinical non-oncology programs targeting chronic bone diseases and Alzheimer's disease.
Cyborg Score Rationale
The company has a trailing twelve-month net income of -$55.8M, indicating significant cash burn typical of early-stage biotech. The July 2025 one-for-twelve reverse stock split signals stock price pressure. However, early clinical data in oncology and analyst attention provide some upside optionality.
Top Insights
NC410 fusion protein showed early clinical activity in colorectal and ovarian cancers when combined with pembrolizumab
SIM0505 Phase 1 dose escalation data expected in Q2 2026
Implemented a one-for-twelve reverse stock split in July 2025 while maintaining NASDAQ listing
Company employs approximately 40 full-time employees
Named Competitors
BriaCell Therapeutics — Clinical-stage immunotherapy for cancer
Biovie — Clinical-stage biopharmaceutical company
APOLLOMICS — Oncology-focused biotech
Carisma Therapeutics — Cell therapy for cancer
Recent Developments
(January 2026) Provided updates on ADC programs LNCB74 and SIM0505 with year-end 2025 cash position disclosure
(July 2025) Completed one-for-twelve reverse stock split following stockholder approval
(Q2 2026 expected) SIM0505 Phase 1 dose escalation data anticipated
Open the full interactive NextCure, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.